AEterna Zentaris AEZS 1000% Chance !? (Seite 525)

[herrscher2]

Regarding KE, we expect to report top-line results in the third quarter 2016.

[herrscher2]

Richtungsweisende Aussagen zu Zoptrex waren doch immer für 3.Qu 2016 terminisiert. Was kommt statt dessen - eine KE??

[centgreifer]

Antwort auf Beitrag Nr.: 53.131.224 von daxt am 24.08.16 22:12:12

Zitat von daxt: Sollte ich mit meiner Chartanalyse Recht haben, dann werden wir morgen an der 3.61$-Marke abprallen und sehr positiv abschließen.


Wenn nicht, kann man kurzfristig überlegen wieder raus zu gehen

PS: Sollten nicht bis Ende August die Ergebnisse zu Macrilen eintrudeln???

Aeterna Zentaris' (AEZS) CEO David Dodd on Q2 2016 Results -

http://seekingalpha.com/article/3998386-aeterna-zentaris-aez…
Aug. 10, 2016 1:38 PM ET

David Dodd
Good morning and thank you for joining us. This is an exciting time for Aeterna Zentaris. We are approaching a major inflection point for our company as we expect to complete two pivotal Phase 3 studies during the coming months and report top-line results for the Macrilen confirmatory study prior to yearend.
Regarding Zoptrex, we expect to report top-line results in the first quarter 2017. I will say more about this later, but let me first provide a brief summary of our achievements during the second quarter.


......But as a result our current expectation is the clinical portion of the trial will conclude by the end of October, and that we will report top-line results during the first quarter of 2017.



Swayampakula Ramakanth
Good morning, David and team. Thank you for taking my questions. The first question is regarding Macrilen program. So when - by the time you’re done with the study and I want to understand what sort of top-line data can we expect on this before you put out your full analysis of the data?

Richard Sachse
Yes, thanks, RK, for this question. As you mainly aware, we are comparing in the study our test with the gold-standard, the insulin tolerance test. And in this respect, the primary endpoint will be the positive and negative agreements with the insulin tolerance tests and also the overall agreement. And this is actually then reflected in our top line results that we will analyze the primary endpoint.
In addition to this, the study is, from an operational point, a little bit complex, although the design is very straight forward. And this is related due to the fact that we have enrolled approximately 25% of the patient with a high likelihood of having the disease, 25% of the patients having a low likelihood of the disease and the rest of them will have an intermediate likelihood or will be healthy volunteers.
We also need to ensure that we will have approximately 25% of the patients coming from the U.S. and this will all be then analyzed in subsequent sub-analysis. But again, the primary endpoint is really the agreement with the gold-standard insulin tolerance tests.


Ende August?

[centgreifer]

Antwort auf Beitrag Nr.: 53.148.186 von Turnover15 am 26.08.16 21:10:52

EXPLOSION?
IMPLOSION?

???KONFUSION???

[Turnover15]

Antwort auf Beitrag Nr.: 53.146.707 von herrscher2 am 26.08.16 17:23:19

eher Implosion

[herrscher2]

Explosion

[lunatics]

Hauptsache es geht weiter nach oben.

[daxt]

Sollte ich mit meiner Chartanalyse Recht haben, dann werden wir morgen an der 3.61$-Marke abprallen und sehr positiv abschließen.


Wenn nicht, kann man kurzfristig überlegen wieder raus zu gehen

PS: Sollten nicht bis Ende August die Ergebnisse zu Macrilen eintrudeln???

[centgreifer]

Antwort auf Beitrag Nr.: 53.129.259 von Maggi110 am 24.08.16 17:42:49

Dann bring doch mal die Würze rein!

[Maggi110]

Schlimmer geht nimmer dieser Thread.....